Literature DB >> 2992106

Itraconazole treatment of murine aspergillosis.

J R Graybill, J Ahrens.   

Abstract

ICR mice were challenged with conidia of Aspergillus fumigatus given either intranasally or intravenously, and treated beginning 1 day later with itraconazole, amphotericin B, or the vehicles for these two agents. Mice challenged intravenously and treated with either antifungal drug had prolonged survival over controls, and had lower tissue counts in the kidneys than the controls. However, mice challenged intranasally had neither prolonged survival nor lower lung tissue counts than the controls.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2992106     DOI: 10.1080/00362178585380321

Source DB:  PubMed          Journal:  Sabouraudia        ISSN: 0036-2174


  11 in total

Review 1.  In vitro and in vivo evaluation of antifungal agents.

Authors:  A Espinel-Ingroff; S Shadomy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-04       Impact factor: 3.267

Review 2.  Overview of medically important antifungal azole derivatives.

Authors:  R A Fromtling
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

3.  Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis.

Authors:  D V Savani; J R Perfect; L M Cobo; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

4.  Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals.

Authors:  J Van Cutsem; F Van Gerven; P A Janssen
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

5.  Evaluation of Bay R 3783 in rodent models of superficial and systemic candidiasis, meningeal cryptococcosis, and pulmonary aspergillosis.

Authors:  R F Hector; E Yee
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

6.  Isolation and characterization of a pigmentless-conidium mutant of Aspergillus fumigatus with altered conidial surface and reduced virulence.

Authors:  B Jahn; A Koch; A Schmidt; G Wanner; H Gehringer; S Bhakdi; A A Brakhage
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

7.  Efficacy of intravenous itraconazole against experimental pulmonary aspergillosis.

Authors:  H M Miyazaki; S Kohno; Y Miyazaki; K Mitsutake; K Tomono; M Kaku; H Koga; K Hara
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

8.  Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma.

Authors:  J Berenguer; N M Ali; M C Allende; J Lee; K Garrett; S Battaglia; S C Piscitelli; M G Rinaldi; P A Pizzo; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

9.  Use of DBA/2N mice in models of systemic candidiasis and pulmonary and systemic aspergillosis.

Authors:  R F Hector; E Yee; M S Collins
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

Review 10.  Azole antifungal agents: emphasis on new triazoles.

Authors:  M S Saag; W E Dismukes
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.